|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gayatri Khanvilkar, MPharm, Ajit Bhagat, Sangmesh Torne, PhD, Tejas Gunjikar, PhD, and Amina Faham, PhD, present a case study showing that previously unviable APIs can be successfully processed with the right methods, which should give hope to formulators facing similar difficulties.
|
|
|
Contributor Cindy Dubin speaks with several leading excipient manufacturers on how their excipient offerings are improving drug release, solubility, taste, physical characteristics, viscosity, and more for a range of molecules.
|
|
|
William Small, PhD, and Arsalan Khan say drug degradation can have toxicological effects in many instances, and it is imperative that this mechanism be minimized as much as possible. The best solution to this is to ensure that appropriate ingredients, both high in quality and purity, are chosen and used throughout the entire drug product lifecycle.
|
|
|
Esay Okutgen, PhD, Alper Orhan, MSc, and Josef Bossart, PhD, believe with the 30-year anniversary of the first product approval using PEG (polyethylene oxide polymer) conjugation, it seems an appropriate occasion to review the evolution of the technology (PEGylation) and subsequent product approvals.
|
|
|
|
|
|
|
|
|

AbbVie is devoted to the discovery, development, manufacturing, and marketing of products that span the continuum of care in pharmaceutical therapies. Leading-edge science and technologies that hold the potential for improving lives are advanced through AbbVie’s dedication to research. Our uniqueness is created by the work we do – producing innovative medicines, continually investing in our pipeline, and giving back to create healthier, more vibrant communities. We have sustained our success by staying true to the key principles on which our company was forged: innovative care and a desire to make a meaningful difference in all that we do. Click here for more.
|
|
|
|
|
|
 |
|
Through this recent license agreement, SIRION Biotech GmbH has granted Cellectis non-exclusive right under its proprietary lentiviral transduction….
|
|
 |
|
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
|
|
 |
|
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….
|
|
 |
|
Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….
|
|
|
|
|
Upcoming eNewsletter Features:
January 20 – Drug Delivery
January 27 – Bioavailability
|
|
|
|
|
|
|
|